Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
MODERIL (rescinnamine) is an oral tablet small-molecule antihypertensive approved in 1956 by Pfizer. Rescinnamine is an alkaloid derivative that works as a sympatholytic agent to reduce blood pressure. It represents a legacy antihypertensive from the rauwolfia alkaloid class, now largely displaced by modern agents.
With LOE approaching and minimal modern commercial infrastructure, team size and budgets are likely minimal; career growth limited to maintenance mode.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job openings and approaching LOE, career opportunities on MODERIL are extremely limited and unlikely to offer advancement or skill development. Assignment to this product is typically a legacy stewardship role with minimal team infrastructure and budget allocation.
Worked on MODERIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.